Sexual Function Research Peptides

3 research peptides demonstrate sexual function properties. This collection covers their mechanisms, evidence base, and research applications.

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide recognized for its role as a non-selective melanocortin receptor agonist, specifically targeting MC3R and MC4R. Unlike traditional therapies such as PDE5 inhibitors that primarily enhance vascular blood flow, PT-141 operates through the central nervous system, modulating the melanocortin system to enhance sexual desire and arousal in both men and women. Research indicates that PT-141's activation of MC4R in the central nervous system leads to increased dopamine release in key brain regions associated with sexual motivation, such as the nucleus accumbens. Furthermore, the peripheral activation of MC1R may result in transient increases in blood pressure and skin pigmentation. In men, the erectogenic effects of PT-141 are believed to be a consequence of central stimulation of nitric oxide production within penile tissues, highlighting its unique mechanism of action. The compound has a half-life of approximately 2-6 hours, which is relevant for its pharmacokinetic profile in clinical contexts.

Melanotan II (MT-II) is a synthetic cyclic heptapeptide that serves as an analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) and acts as a non-selective agonist of melanocortin receptors ranging from MC1R to MC5R. Initially developed for its photoprotective properties to enhance skin tanning, MT-II has also been implicated in modulating sexual function and appetite through its action on MC3R and MC4R. Notably, PT-141 was identified as an active metabolite of MT-II, specifically responsible for its effects on sexual arousal. Despite its potential applications, MT-II is not approved for human use in any jurisdiction, and various regulatory bodies have issued warnings regarding its safety. The non-selective activation of multiple melanocortin receptors simultaneously may lead to a range of physiological effects, including increased sexual desire and appetite suppression, which complicates the interpretation of its effects compared to the more targeted actions of PT-141.

Bremelanotide, a cyclic heptapeptide with a molecular weight of approximately 1025.2 g/mol, functions as an agonist at melanocortin receptors MC3R and MC4R. Its primary mechanism involves central activation of these receptors, particularly within hypothalamic nuclei that regulate sexual arousal and desire. Distinct from phosphodiesterase inhibitors that enhance peripheral blood flow, bremelanotide's action is centered on modulating neural pathways related to sexual motivation. Activation of MC4R in areas such as the medial preoptic area and paraventricular nucleus initiates downstream signaling cascades involving oxytocin and dopamine, both of which are critical in the regulation of sexual behavior. The peptide's structure includes the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, and it exhibits a half-life of approximately 2.7 hours. Bremelanotide has been FDA-approved under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women, marking a significant advancement in therapeutic options for sexual health.